Crown Bioscience , a global contract research organization and JSR Life Sciences company, announced the opening of a new location in Singapore to expand the company’s capacity to serve both global and support local biotech and pharmaceutical companies engaged in the discovery and development of preclinical and translational oncology drugs.
The new facility will initially provide a broad portfolio of in-demand cell line-derived xenograft (CDX) and syngeneic models, in addition to supporting analytical biomarker capabilities, including flow cytometry and pathology services. The company is also working with Singapore’s established biomedical community to bring to Singapore not only the fundamental capabilities of Crown Bioscience’s preclinical services, but also new technologies and services.
This announcement is official in its original source language. Translations are only intended as a reading aid and must be compared with the text in the source language, which is the only one legally valid.